lesabelimab (BC003) / Dragon Boat Biopharmaceutical, Adagene - LARVOL DELTA

Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=66 | Completed | Sponsor: Dragonboat Biopharmaceutical Company Limited | Unknown status ➔ Completed | N=130 ➔ 66

Enrollment change • Trial completion • Oncology • Solid Tumor

An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: Dragonboat Biopharmaceutical Company Limited | Recruiting ➔ Completed | N=130 ➔ 12

Enrollment change • Trial completion • Oncology • Solid Tumor

the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors (clinicaltrials.gov) - P2 | N=27 | Completed | Sponsor: Dragonboat Biopharmaceutical Company Limited | Recruiting ➔ Completed | N=127 ➔ 27

Enrollment change • Trial completion • Bladder Cancer • Genito-urinary Cancer • Kidney Cancer • Oncology • Penile Cancer • Renal Cell Carcinoma • Solid Tumor